Mission GBM
Subscribe
Sign in
Home
Archive
About
New
Top
Another Birthday
Thank You for the notes of well wishes and inquiry over the past few months regarding Julie. From a brain cancer perspective, she has been doing well…
Nov 8
•
Scott L. Rakestraw, PhD
9
Share this post
Another Birthday
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
June 2023
Breakthrough Results from the INDIGO Trial of Vorasidenib in Low Grade Glioma (LGG)
Great news for IDH-mutant LGG patients…and an object lesson in investable theses for brain cancer
Jun 7
•
Scott L. Rakestraw, PhD
5
Share this post
Breakthrough Results from the INDIGO Trial of Vorasidenib in Low Grade Glioma (LGG)
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
April 2023
Immuno-Oncology: A Question of Balance
A SARS-CoV-2 infection precipitates a cascading series of immunological adverse events
Apr 15
•
Scott L. Rakestraw, PhD
9
Share this post
Immuno-Oncology: A Question of Balance
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
February 2023
Results That Matter
Team Julie delivers a remarkable outcome based on leading edge clinical science
Feb 2
•
Scott L. Rakestraw, PhD
16
Share this post
Results That Matter
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
January 2023
The Central Hypothesis of Immunotherapy and Its Application to Brain Cancer
Rapid advances raise the bar on what can be achieved for patients
Jan 30
•
Scott L. Rakestraw, PhD
2
Share this post
The Central Hypothesis of Immunotherapy and Its Application to Brain Cancer
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
A Year in the Life
Charting the journey over 365 days of living with GBM
Jan 19
•
Scott L. Rakestraw, PhD
15
Share this post
A Year in the Life
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Day One Biopharmaceuticals Announces Top Line Data for the FIREFLY-1 Pivotal Phase 2 Trial in Pediatric Low Grade Glioma
Meaningful clinical responses to tovorafenib suggest an important new tool in the Brain Cancer Toolbox
Jan 12
•
Scott L. Rakestraw, PhD
2
Share this post
Day One Biopharmaceuticals Announces Top Line Data for the FIREFLY-1 Pivotal Phase 2 Trial in Pediatric Low Grade Glioma
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Stanford's Innovative Medicines Accelerator and The Invus Group Collaborate to Attack GBM
An important and visionary partnership featuring multiple members of Team Julie
Jan 10
•
Scott L. Rakestraw, PhD
4
Share this post
Stanford's Innovative Medicines Accelerator and The Invus Group Collaborate to Attack GBM
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
December 2022
Meet the Team: David W. Andrews, MD
Neurosurgeon "par excellence" and Biotech entrepreneur
Dec 27, 2022
•
Scott L. Rakestraw, PhD
5
Share this post
Meet the Team: David W. Andrews, MD
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Meet the Team: Michael L. Dougan, MD, PhD
Optimizing Immuno-Oncology treatment by overcoming immune-related Adverse Events (irAEs)
Dec 21, 2022
•
Scott L. Rakestraw, PhD
4
Share this post
Meet the Team: Michael L. Dougan, MD, PhD
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
One Year Later: A Winter Celebration
We travel to the wedding of a dear friend's daughter in snowy Vermont
Dec 19, 2022
•
Scott L. Rakestraw, PhD
16
Share this post
One Year Later: A Winter Celebration
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Big News: Moderna and Merck Report Phase 2b Data for an mRNA Cancer Vaccine + Pembrolizumab
Further Evidence that the Central Hypothesis is gaining traction in cancer immunotherapy
Dec 14, 2022
•
Scott L. Rakestraw, PhD
5
Share this post
Big News: Moderna and Merck Report Phase 2b Data for an mRNA Cancer Vaccine + Pembrolizumab
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts